PDCD1 and cutaneous melanoma: Turning to cutaneous melanoma, a large proportion of patients have already received anti-PD-1 treatment in adjuvant or neoadjuvant setting [24], or have developed primary and/or secondary resistance in the advanced setting, and treatment with the comination of ipilimumab and nivolumab is associated with higher toxicity [32].